Oligonucleotide Synthesis Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Merck KGaA, and Integrated DNA Technologies
Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Synthesis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.
Global Oligonucleotide Synthesis Market to Reach USD 8.6 Billion by 2035, Driven by Precision Medicine and Therapeutic Innovation
The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025 and is projected to reach USD 8.6 billion by 2035, expanding at a compound annual growth rate of 12.5%. Market growth is being supported by an expanding pipeline of oligonucleotide therapeutics, increased use of synthetic oligonucleotides in clinical and research applications, and continued commercialization of precision medicine and gene-editing technologies.
Oligonucleotide synthesis remains an essential enabling technology for pharmaceutical development, molecular diagnostics, genomic research, and synthetic biology. Growing investment in advanced manufacturing facilities, combined with rising demand for high-quality nucleic acid components, is expected to support sustained market expansion. The broader adoption of molecular diagnostic platforms and personalized treatment strategies is also increasing demand for customized oligonucleotides across healthcare, biotechnology, and academic research organizations.
Products and Services Segment Maintains Market Leadership
The products and services segment accounted for 53% of the global oligonucleotide synthesis market and is forecast to grow at a CAGR of 12.05% from 2026 to 2035. The segment includes commercial synthesis services providing research-grade, analytical-grade, and Good Manufacturing Practice-grade oligonucleotides tailored to specific sequence lengths, purity standards, and chemical modification requirements.
This segment's leading position reflects the critical role of commercial synthesis providers in supporting applications ranging from early-stage scientific research to pharmaceutical development, clinical trials, and commercial manufacturing. Providers are expanding production capacity and introducing advanced synthesis platforms to improve quality, scalability, and delivery times.
Pharmaceutical and Biotechnology Companies Drive Demand
Pharmaceutical and biotechnology companies held a 55% market share and are projected to register a CAGR of 12.65% through 2035. Synthetic oligonucleotides are increasingly used throughout drug development, including target discovery, lead optimization, preclinical testing, clinical manufacturing, and commercial production.
To improve supply reliability and maintain regulatory compliance, drug developers are establishing long-term agreements with GMP-certified oligonucleotide synthesis providers. These partnerships help secure manufacturing capacity, reduce operational risks, and support the advancement of oligonucleotide-based therapeutics through clinical and regulatory milestones.
North America Benefits from a Strong Biotechnology Ecosystem
The North America oligonucleotide synthesis market generated USD 955.9 million in 2025. Regional growth is supported by an established pharmaceutical and biotechnology industry, extensive research infrastructure, federal funding programs, and significant investment in genomic medicine.
The United States accounts for most of North America's market revenue due to its concentration of clinical-stage biotechnology companies, leading research institutions, and specialized oligonucleotide synthesis technology and manufacturing providers. Continued development of RNA-based medicines, gene-editing platforms, and precision diagnostic solutions is expected to reinforce regional demand.
Competitive Landscape and Growth Strategies
Key companies operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Integrated DNA Technologies, LGC Biosearch Technologies, Bioneer, Eurogentec, Azenta Life Sciences, Eurofins, Maravai LifeSciences, GenScript, Twist Bioscience, Merck, and Agilent.
Market participants are strengthening their competitive positions by expanding manufacturing capacity, enhancing GMP-compliant production, and investing in synthesis technologies that improve scalability, consistency, and turnaround times. Companies are also broadening their portfolios with customized oligonucleotide products featuring varied purity levels, sequence formats, and chemical modifications.
Strategic collaborations with pharmaceutical companies, biotechnology firms, and research organizations remain central to securing long-term contracts and supporting therapeutic development pipelines. Geographic expansion, new production facilities, and stronger regional distribution networks are also expected to improve access to oligonucleotide synthesis services worldwide.
Comprehensive Market Analysis and Forecast
Key Topics Covered:
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy & data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail & confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Base year calculation for any one approach
1.8 Forecast model
1.8.1 Quantified market impact analysis
1.8.1.1 Mathematical impact of growth parameters on forecast
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Product type trends
2.2.3 Application trends
2.2.4 End use trends
2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Expanding Applications in Molecular Diagnostics and Precision Medicine.
3.2.1.2 Growing Prevalence of Diseases Globally.
3.2.1.3 Rapid Technology Advancements in Synthetic Biology.
3.2.1.4 Rising Investments Towards Research and Development Activities
3.2.2 Industry pitfalls and challenges
3.2.2.1 Stringent Government Regulations and Guidelines.
3.2.2.2 High Cost, Biosafety, Biosecurity, and Ethical Issues.
3.2.3 Market opportunities
3.2.3.1 Untapped Potential in Emerging Markets for Research-Grade Oligo Demand
3.2.3.2 Emergence of High-Complexity Oligo Pools for Synthetic Biology & CRISPR Screening
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 North America
3.4.2 Europe
3.4.3 Asia-Pacific
3.5 Technology and innovation landscape
3.5.1 Current technological trends
3.5.2 Emerging technologies
3.6 Pricing trend analysis (Driven by Primary Research)
3.7 Future market trends
3.8 Impact of AI & Generative AI on the market (Driven by Primary Research)
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.2.3 Asia-Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 ($ Mn)
5.1 Key trends
5.2 Oligonucleotide Synthesis
5.2.1 Standard oligonucleotide synthesis
5.2.2 Custom oligonucleotide synthesis
5.3 Reagents and Consumables
5.4 Equipments
Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)
6.1 Key trends
6.2 Research
6.2.1 Synthetic biology
6.2.2 Drug discovery
6.2.3 Other research applications
6.3 Therapeutics
6.3.1 Neurology
6.3.2 Rare diseases
6.3.3 Cardiovascular disease
6.3.4 Infectious diseases
6.3.5 Other therapeutic areas
6.4 Diagnostics
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
7.1 Key trends
7.2 Pharmaceutical and biotechnology companies
7.3 Academic and research institutes
7.4 Contract research organization
7.5 Other end users
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia-Pacific
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 Agilent Technologies
9.2 Azenta Life Sciences
9.3 Bioneer
9.4 Eurofins
9.5 Eurogentec
9.6 GenScript
9.7 Integrated DNA Technologies
9.8 LGC Biosearch Technologies
9.9 Maravai LifeSciences
9.10 Merck
9.11 Thermo Fisher Scientific
9.12 Twist Bioscience
For more information about this report visit https://www.researchandmarkets.com/r/3uett7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.